Giraldo, P. Et Al. 2023. ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3. 19th Annual World Symposium , (Florida, United States Of America), 47-48.

Giraldo, P., GÖKÇAY, G. F., Batsu, I., Kissell, J., Perichon, M. G., & Drelichman, G. I., (2023). ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3 . 19th Annual World Symposium (pp.47-48). Florida, United States Of America

Giraldo, Pilar Et Al. "ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3," 19th Annual World Symposium, Florida, United States Of America, 2023

Giraldo, Pilar Et Al. "ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3." 19th Annual World Symposium , Florida, United States Of America, pp.47-48, 2023

Giraldo, P. Et Al. (2023) . "ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3." 19th Annual World Symposium , Florida, United States Of America, pp.47-48.

@conferencepaper{conferencepaper, author={Pilar Giraldo Et Al. }, title={ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3}, congress name={19th Annual World Symposium}, city={Florida}, country={United States Of America}, year={2023}, pages={47-48} }